Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind active-controlled trial of a 13-valent pneumococcal conjugate vaccine in healthy infants and children aged 6 weeks to under 6 years
CTR20233341Phase 3Active
- Sponsor
- Sino Biopharmaceutical Limited
- Start
- Oct 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of pneumococcal 13-valent conjugate vaccine in pneumococcal disease, sponsored by Sino Biopharmaceutical Limited. Started Oct 2024; status: active.
02
Drugs
pneumococcal 13-valent conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on CTR20233341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233341.